Everyone who reads comics knows that winning is about recognising the villains, choosing the superhero with precisely the right ‘superpowers’ to overcome the bad guy, and sitting back to enjoy the action. The last two decades have been exciting times in the battle against autoimmune diseases. The villains have been elucidated owing to a growing understanding of the immunological mechanisms underlying the co-ordinated interaction between T and B cells and pro-inflammatory cytokines responsible for systemic inflammation, followed by the development of targeted biologic drugs with ‘superpowers’ against specific immune cells or cytokines. These biologic therapies have dramatically improved outcomes in patients with rheumatological and autoimmune diseases. Nine biologic drugs are currently available in South Africa (SA) – all showing good efficacy and safety profiles. Their high cost and potential adverse events preclude them from being used as first-line agents. They are therefore indicated for severe disease refractory to standard therapies, and their use must be initiated by a specialist. The most important adverse effect of this class of drugs is infection and, in SA, tuberculosis is of particular concern. As new targets in the immune system are identified, new biologics will be developed. The current challenges are to optimise standard care for all patients with autoimmune diseases, and to offer the appropriate biologic to patients with refractory disease.

Biologic therapies have made an enormous impact on severe RA by modulating disease activity and retarding radiographic damage, thus preventing disability. Patients with active disease despite synthetic DMARDs are reserved for patients with severe disease who fail to respond to standard treatments. In SA, the use of biologic therapies needs to be initiated by a specialist, who follows the guidelines published online by the relevant specialist associations, including the South African Gastroenterology Society (www.SAGES.co.za),[1] the South African Rheumatology Association (www.SARAA.co.za),[2] and the Dermatology Society of South Africa (www.DERMA.co.za).[2]

**Rheumatoid arthritis**

Biologic therapies have made an enormous impact on severe RA by modulating disease activity and retarding radiographic damage, thus preventing disability. Patients with active disease despite synthetic DMARDs over at least six months can be considered candidates...
for biologic therapy. Seven of the currently available biologics are registered for first-line use in RA, and systemic reviews suggest that these biologics have similar efficacies.\(^3\),\(^4\) The choice of drug depends on the side-effect profile, disease characteristics, patient preferences for route of administration, and cost. Because of the high risk of tuberculosis (TB) in SA, particularly associated with TNF-\(\alpha\), biologic drugs with an alternative mode of action may be the most appropriate choice as first-line therapy.\(^5\) In addition, certain disease features may guide the choice of drug, e.g. rheumatoid factor-negative patients are less likely to respond to rituximab, and those with pronounced systemic symptoms (such as anaemia of chronic disorders, high C-reactive protein and fatigue) are likely to have a good response to

---

**Table 1. Biologic drugs in South Africa**

<table>
<thead>
<tr>
<th>Biologic drug</th>
<th>Mechanism of action</th>
<th>Route of administration</th>
<th>Registered indications</th>
<th>Off-label indications</th>
<th>Major adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infliximab (Revellex)</td>
<td>Mouse/human chimeric mab against TNF-(\alpha)</td>
<td>IV every 8 weeks</td>
<td>RA, AS, PS, PSA, CD, UC, PaedCD, PaedUC</td>
<td>JIA, SJIA, uveitis, Takayasu arteritis, GCA, pyoderma gangrenosum, sarcoidosis</td>
<td>Serious infections, including: tuberculosis, hepatitis B reactivation, demyelinating disorders</td>
</tr>
<tr>
<td>Etanercept (Enbrel)</td>
<td>Soluble TNF-(\alpha) receptor fusion protein</td>
<td>SC weekly</td>
<td>RA, AS, PS, PSA, JIA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adalimumab (Humira)</td>
<td>Mab against TNF-(\alpha)</td>
<td>SC every other week</td>
<td>RA, AS, axial spondyloarthropathies, PS, PSA, CD, UC, JIA, PaedCD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Golimumab (Simponi)</td>
<td>Human mab against TNF-(\alpha)</td>
<td>SC monthly</td>
<td>RA, AS, PSA, UC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Certolizumab pegol†</td>
<td>Human mab against TNF-(\alpha)</td>
<td>SC monthly</td>
<td>RA,* CD,* AS,* PSA*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abatacept (Orencia)</td>
<td>Receptor fusion protein inhibiting T-cell co-stimulation</td>
<td>IV monthly or SC weekly</td>
<td>RA, JIA</td>
<td></td>
<td>SLE</td>
</tr>
<tr>
<td>Rituximab (Mabthera)</td>
<td>Mouse/human chimeric mab against CD 20(^{\text{th}}) B cells</td>
<td>IV 6-monthly</td>
<td>RA, ANCA-associated vasculitis, haematological malignancies, NHL, CLL</td>
<td>SLE, pemphigus vulgaris, inflammatory myopathies</td>
<td>Serious infections: hepatitis B reactivation, progressive multifocal leucoencephalopathy</td>
</tr>
<tr>
<td>Tocilizumab (Actemra)</td>
<td>Humanised IL-6 receptor antibody</td>
<td>IV monthly</td>
<td>RA, SJIA, JIA*</td>
<td>Castleman’s, CD, relapsing polychondritis, SLE, SScI, PMR, RS3PE</td>
<td>Infection: neutropenia, transaminitis, dyslipidaemia, GI perforation</td>
</tr>
<tr>
<td>Ustekinumab (Stelara)</td>
<td>IL-12/23 monoclonal antibody</td>
<td>PS, PSA,* CD*</td>
<td>UC</td>
<td></td>
<td>Serious infections</td>
</tr>
</tbody>
</table>

ANCA = anti-neutrophilic cytoplasmic antibody; AS = ankylosing spondylitis; CD = Crohn’s disease; CLL = chronic lymphocytic lymphoma; GCA = giant cell arthritis; GI = gastrointestinal; IL = interleukin; IV = intravenous; JIA = juvenile idiopathic arthritis; NHL = non-Hodgkin lymphoma; Paed = paediatrica; PMR = polymyalgia rheumatica; Ps = psoriasis; PM = polymorphic arthritis; RA = rheumatoid arthritis; RS3PE = relapsing seronegative symmetrical synovitis with pitting oedema; mab = monoclonal antibody; SC = subcutaneous; SJIA = systemic juvenile idiopathic arthritis; SLE = systemic lupus erythematosus; SSc = systemic sclerosis; TNF = tumour necrosis factor; UC = ulcerative colitis.

*Registration pending.
†Currently not available in South Africa.
secukinumab (an interleukin (IL)17A inhibitor) may be useful. Abatacept and tocilizumab have shown only limited success in AS. In an alternative TNFi may be efficacious. Other biologics (rituximab, abatacept and tocilizumab) have shown only limited success in AS. In future, secukinumab (an interleukin (IL)17A inhibitor) may be useful.

**Psoriasis**

Persistent severe plaque psoriasis resistant to standard therapies is an indication for TNFi therapy. Similarly, PsA (including peripheral arthritis, axial disease, enthesitis and dactylitis) has shown a rapid and significant response to TNFi with inhibition of radiographic disease progression. More recently, ustekinumab, an IL-12/IL-23 monoclonal antibody, has been shown to be effective in psoriasis and PsA, but is currently only registered for plaque psoriasis. In addition, drugs inhibiting IL-17 seem promising, particularly for skin disease and enthesitis.

**Inflammatory bowel disease**

In Crohn’s disease, monoclonal antibodies that inhibit TNF (but not TNF receptor blockers) are beneficial in steroid-refractory, steroid-dependent, or complex fistulising disease. This induction therapy needs to be continued for at least 12 months in patients who show a response. The TNFi is usually prescribed together with an immunosuppressive agent, with evidence particularly favouring azathioprine. Similarly, TNFi are also effective for treatment-refractory, moderate, or severely active ulcerative colitis. Patients with IBD-associated axial or peripheral arthritis refractory to sulfasalazine may also benefit from TNFi. Ustekinumab has been shown to be useful in TNF-resistant Crohn’s disease.

**Juvenile idiopathic arthritis**

Biologic drugs have greatly improved outcomes in refractory polyarticular and oligoarticular juvenile idiopathic arthritis (JIA), and TNFi have been the most widely studied biologics in these diseases. A recent systematic review demonstrated that etanercept, adalimumab and abatacept were equally efficacious. Refractory systemic JIA has shown good response to tocilizumab, and to IL-1 inhibitors including anakinra, canakinumab and rilonectin and encouraging study results have been reported with tofacitinib. The IL-1 inhibitors and tofacitinib are not yet licensed in SA.

**Systemic lupus erythematosus**

Despite initial optimism that biologic drugs would lead to new therapeutic options, most clinical trials in SLE have missed their primary endpoints. Belimumab inhibits B-cell activation factor, which is also known as B-lymphocyte stimulator. It has been shown to reduce flares and antibody titres in mild to moderate SLE (excluding renal or central nervous system (CNS) involvement) and is the only biologic registered in the USA for use in SLE. Rituximab (for haematological, renal and CNS involvement), abatacept (for arthritis), and TNFi (for skin and joint disease) have been successfully used off-label.

**ANCA-associated vasculitis, uveitis and Behçet’s syndrome**

Rituximab is one of the few biologics to have been studied in anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis, and has been shown to be non-inferior to cyclophosphamide for induction therapy.

Although no randomised controlled trials have been published, observational studies have shown benefit in cyclophosphamide-resistant disease. In refractory Behçet’s disease, both TNFi infliximab and adalimumab were effective, also for severe ocular inflammation, whereas etanercept was less effective for ocular or gastrointestinal manifestations.

**IgG4 sclerosing-related disease**

Immunoglobulin (Ig) G4-related disease is a rare, recently characterised, immune-mediated fibrosing disorder, with varying clinical manifestations depending on the specific organ system involved. Mainstay treatment is corticosteroids, but immunosuppressants may be added in relapsing patients or as steroid-sparing agents. Rituximab may be useful in refractory patients.

**Adverse effects of biologics**

While the efficacy of biologic drugs has been clearly established, the risk of adverse effects has been uncertain, and has only recently been clarified by Cochrane meta-analysis and by literature review.

Table 1 summarises the major adverse effects of various biologics available in SA. A great concern with all biologic treatments, with the exception of abatacept, is the increased risk of community-acquired and opportunistic infections. Of particular importance in SA is the risk of TB infection or reactivation, which is only partially addressed...
by screening for latent TB infection and isoniazid prophylaxis. In studies conducted in countries with a low TB prevalence, the risk of TB seems highest among patients receiving monoclonal TNF inhibitors during their first year of treatment and rises as high as a 56-fold increased incidence compared with the general population.[20-22] Although initially of concern, malignancies do not seem to increase in patients using biologics except for a possible increase in melanoma associated with TNF inhibitors.[23]

Switching and withdrawing biologic therapy

Despite impressive results in the majority of patients, response to a specific biologic drug is unpredictable and up to one-third of patients with an autoimmune disease requiring biologic therapy have a poor response or lose their response. These patients may respond to switching to another biologic drug. The search for biomarkers to allow optimal selection of biologic drugs is ongoing.

Given the costs and potential adverse effects, withdrawal or reduction of biologic therapy is a goal of many patients and physicians. In RA, AS and PsA, this may be possible in a subset of patients who have achieved long-term remission, particularly in those with early disease, and studies are ongoing.[26] In the case of IBD, withdrawal of TNF inhibitor therapy in patients who have been in clinical remission ≥12 months appears safe in the majority of patients.

Vaccination

Because of the increased risk of serious infections in patients using biologics, vaccination is an important preventive strategy.[25,26] Current recommendations are that vaccines, particularly influenza and pneumococcal vaccines, be given prior to biologic therapy where possible, and that live vaccines (including measles, mumps, rubella, live attenuated influenza, varicella zoster, yellow fever, Ty21a oral typhoid, bacillus Calmette-Guérin (BCG), and rotavirus vaccines) are contraindicated.[27]

Cost of biologic drugs

One of the major problems restricting biologic use in SA is their cost, ranging between R110 000 and R160 000 annually. Offset against this cost is the benefit of early disease control, thus reducing the impact of the disease on functional capabilities and work productivity. A recent French study demonstrated that even though early biologic therapy in RA was costly, it resulted in lower health-associated costs (including physician consultations, investigations and hospitalisation) over a 4-year period owing to better disease control.[28] Long-term studies in SA are needed to evaluate the cost of biologics against the economic burdens of poorly controlled disease.

Healthcare providers and patient groups in SA need to lobby for wider access to biologics for patients who require them, in both the private and state sectors. This might entail pharmaceutical companies offering drugs at reduced prices, greater flexibility by medical schemes for patients with limited cover, and the use of biosimilar drugs.

Biologic registries

Biologic registries are a major source of efficacy and safety data, and a registry of rheumatology patients who are on biologic therapy has been in operation in SA since 2008. A recent paper describes the SA experience of TNF inhibitor therapy in RA, showing results similar to those seen elsewhere in the world.[29] Further clinical research, using the epidemiological data from the SA registry, will help to develop evidence-based treatment guidelines with regard to TB risks and latent TB detection, strategies to monitor patients on biologics, and long-term cost-effectiveness of treatment.

Conclusion

Ben Parker, uncle to Peter Parker a.k.a Spiderman, remarked ‘With great power comes great responsibility’. So it is with biologic drugs. As our knowledge of the underlying mechanisms of autoimmune diseases expands, we can expect more targeted therapies to be developed. Our growing experience with biologics and their adverse events will include development of clinical and laboratory biomarkers to allow selection of optimal therapy for each patient. The current and future challenges in SA are to optimise the standard care for patients with autoimmune diseases, with careful selection of patients with severe refractory disease and provision of the appropriate biologic drugs.

References


